title: Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
abstract: This report demonstrates a unique case of conjunctival melanoma harboring a BRAF V600E mutation responsive to systemic therapy with BRAF and MEK inhibitors. While systemic therapy would not be appropriate in patients with local disease alone, it may act therapeutically in cases of higher stage ocular surface and eyelid melanoma.
authors.affiliation: *Ophthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School; †Cancer Center, Massachusetts General Hospital, Harvard Medical School; and ‡Department of Ophthalmology, David C. Cogan Laboratory of Ophthalmic Pathology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.
authors.forename: Lora R
authors.initials: LR
authors.lastname: Dagi Glass
authors.forename: Donald P
authors.initials: DP
authors.lastname: Lawrence
authors.forename: Frederick A
authors.initials: FA
authors.lastname: Jakobiec
authors.forename: Suzanne K
authors.initials: SK
authors.lastname: Freitag
mesh_terms: D001706:Biopsy; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D010091:Oximes / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D011728:Pyridones / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*
chemical_list: D007093:Imidazoles; D010091:Oximes; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib